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Abstract: The aspirin–clopidogrel combination is the current gold standard antiplatelet 
regimen following percutaneous coronary intervention and for the treatment of acute coronary 
syndrome. Despite the clinical benefit of this combination, patients continue to have vascular 
events. Another purinergic (P2Y12) receptor antagonist, prasugrel, became available last year. 
Although prasugrel is superior to clopidogrel in reducing clinical endpoints, a higher bleed-
ing rate has been identified particularly in high-risk patients. Ticagrelor, a reversible P2Y12 
receptor antagonist currently being evaluated for approval, is also more potent than clopidogrel 
but has a similar bleeding risk. Two additional P2Y12 antagonists are being investigated that 
will be available as an intravenous formulation. Apart from the P2Y12 receptor antagonists, 
multiple other agents are being developed with unique mechanisms of platelet inhibition. These 
agents are being studied as an alternative to or in combination with clopidogrel. The antiplatelet 
agents currently under development include: thrombin receptor antagonists, phosphodiesterase 
inhibitors, a thromboxane–prostaglandin receptor antagonist, a serotonin receptor blocker, a 
platelet adhesion antagonist, nitric oxide-releasing aspirin, a glycoprotein VI antagonist, and 
a cyclooxygenase inhibitor. The purpose of this review is to describe the efficacy and safety 
profiles of the emerging antiplatelet agents and their role in the treatment of atherosclerotic 
cardiovascular diseases.
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Introduction
Platelets have an important role in primary hemostasis and endothelial repair. In 
addition, by activation of their numerous surface receptors and release of several 
inflammatory mediators, platelets promote atherothrombosis.1 Coronary artery disease 
(CAD), stroke, and peripheral vascular disease are known as “atherothrombotic” 
manifestations of atherosclerosis. Inhibition of platelet aggregation and secretion is 
paramount to reducing adverse outcomes in these clinical conditions associated with 
heightened platelet reactivity.
Aspirin, a cyclooxygenase (COX) inhibitor, has been used for centuries due to 
its   anti-inflammatory, antipyretic, and analgesic properties. More recently, aspirin 
has been used as an antiplatelet agent to prevent thromboembolic vascular events. 
The   thienopyridines are another class of antiplatelet agents that inhibit adenosine 
  diphosphate-induced platelet aggregation via the P2Y12 receptor located on the platelet 
surface. Adenosine diphosphate (ADP) is a very potent platelet agonist, whose signals to 
cause platelet aggregation are mediated via two purinergic platelet receptors, Gq coupled 
P2Y12 receptor and Gi coupled P2Y12 receptor.2 Due to selective tissue   distribution of Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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P2Y12 receptors, the thienopyridines, referred to as P2Y12 
receptor antagonists, are potent antiplatelet agents that are 
extensively used in clinical and interventional cardiology.
Ticlopidine, the first P2Y12 antagonist, is approved 
for use with aspirin as dual antiplatelet therapy following 
  coronary artery stenting.3 However, due to serious side 
effects of   ticlopidine, it is no longer the drug of choice 
having been replaced by clopidogrel, a second generation 
thienopyridine P2Y12 antagonist with a more favorable 
side effect profile. Several large, randomized clinical   trials 
have demonstrated the benefit of aspirin-clopidogrel com-
bination in   reducing death, myocardial infarction (MI), 
and target vessel   revascularization among patients with 
acute coronary syndrome (ACS) including unstable angina, 
non-ST-segment elevation MI (NSTEMI) and ST-segment 
e  levation MI (STEMI) with or without percutaneous   coronary 
  intervention (PCI).4–9 The combination of aspirin and clopi-
dogrel has now become the favored combination in the realm 
of   interventional cardiology following PCI, and also in the 
medical management of patients with ACS.
Clopidogrel has properties that make it less than an ideal 
antiplatelet agent. It has a slow onset of action of at least two 
hours following a 600 mg oral loading dose, and between 
6–15 hours after a 300 mg loading dose to achieve adequate 
platelet inhibition. This delayed onset of action can be 
problematic when quicker platelet inhibition is desired as in 
ACS. In addition, the irreversible blockade of platelet activ-
ity can delay coronary artery bypass graft (CABG) surgery 
for 5–7 days in an effort to reduce the rate of CABG-related 
bleeding and the need for re-operation and transfusion.
Although aspirin and clopidogrel are widely used in the 
management of ACS and after PCI, some patients continue 
to have thromboembolic events. One possible explana-
tion is the concept of antiplatelet resistance the has been 
reported with both aspirin and clopidogrel.10,11 The proposed 
  mechanisms for antiplatelet resistance include, alternative 
signaling pathways for platelet activation, high stress con-
ditions, genetic polymorphisms and drug interactions.10,12 
  Variability in response to clopidogrel therapy has been 
recently   demonstrated on platelet function assays. This 
phenomenon of “clopidogrel hyporesponsiveness” has 
been linked to increased thrombotic events which could be 
potentially fatal.13,14 Tailoring of clopidogrel therapy based 
on platelet reactivity as assessed by in vitro platelet assays 
was met with initial enthusiasm, but this approach has been 
found to be far from ideal.15,16 Genetic polymorphisms with 
reduced function variant alleles of the CYP2C19 hepatic 
cytochrome P450 isoenzyme involved in the metabolism of 
clopidogrel to its active metabolite has been associated with 
platelet hypo-responsiveness.17
As a result of these problems associated with clopidogrel, 
newer agents are being developed with the hope of overcoming 
these shortcomings. Ideally, any agent aimed at replacing clopi-
dogrel would have a faster onset of action and more uniform 
platelet inhibition without a significant increase in bleeding 
risk. In addition to finding a replacement for clopidogrel, some 
antiplatelet agents are being investigated as add-on therapy to 
the combination of aspirin and clopidogrel. Table 1 outlines the 
various classes of antiplatelet agents that are currently available 
or under investigation. We aim to discuss the role of emerging 
antiplatelet agents in atherosclerotic cardiovascular diseases.
Newer P2Y12 antagonists
While ticlopidine and clopidogrel have been used extensively 
ever since their inception, newer agents hold a great deal of 
promise due to their differential pharmacology.18 Table 2 
describes the various types of P2Y12 antagonists that are 
currently in use, or in the later stages of development.
Table 1 Classes of antiplatelet agents
Class Drugs
Cyclooxygenase inhibitors Aspirin 
indobufen
ADP receptor antagonists  
(Thienopyridines)
Ticlopidine 
Clopidogrel 
Prasugrel
ADP receptor antagonists  
(Nonthienopyridines)
Cangrelor 
Ticagrelor 
elinogrel
Glycoprotein iib/iiia inhibitors Abciximab 
Tirofiban 
Eptifibatide 
Defibrotide
Phosphodiesterase inhibitors Dipyridamole 
Cilostazol 
NT-702 (parogrelil 
hydrochloride, NM-702)
Protease-activated receptor (PAR-1) 
inhibitors (thrombin receptor inhibitor)
SCH 530348 
e5555
Thromboxane A2 receptor inhibitor Terutroban (S18886)
Platelet adhesion antagonist ARC1779 
C1qTNF-related 
protein-1 
DZ-697b
Nitric oxide releasing aspirin NCX-4016
Collagen-platelet interaction inhibitor PR-15 
Monoclonal antibodies 
Aptamers 
Small molecule peptide 
inhibitors
Abbreviation: ADP, adenosine diphosphate.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Prasugrel
Prasugrel is a new thienopyridine adenosine diphosphate 
(ADP) receptor antagonist. Like clopidogrel and   ticlopidine, 
prasugrel is a selective and irreversible inhibitor of the platelet 
P2Y12 receptor.19 It is a pro-drug that is converted to its active 
metabolite R-138727 by cytochrome (CYP) P450 enzymes. 
The CYP3A4 and CYP2B6 enzymes are   primarily   responsible 
for metabolic conversion with CYP2C9 and CYP2C19 being 
secondary pathways. For prasugrel,   conversion to the active 
metabolite requires only one CYP450 dependent oxidation 
step, while clopidogrel requires two enzymatic steps. As a 
result, prasugrel has a faster onset of action with a peak plasma 
concentration of the active metabolite 30 minutes post dosing.20 
The half life of the active metabolite of prasugrel is 7.4 hours 
(ranging from 2 hours to 15 hours) while the half life of the 
active metabolite for clopidogrel is 8 hours. Due to the differing 
enzymes involved in metabolic conversion of prasugrel to its 
active form, the drug interaction reported between clopidogrel 
and proton pump inhibitors does not seem to be clinically sig-
nificant.21 Unlike with clopidogrel, common functional CYP 
genetic variants do not affect active drug metabolite levels, 
inhibition of platelet aggregation, or clinical cardiovascular 
event rates in persons treated with prasugrel.22
Early Phase I and II clinical trials demonstrated prasu-
grel has a faster onset of action and more complete platelet 
inhibition compared to clopidogrel. The Joint Utilization of 
Medications to Block Platelets Optimally (JUMBO-TIMI 26) 
trial was the first Phase II study to evaluate the use of prasu-
grel in patients undergoing elective or urgent PCI.23 In this 
study, 904 patients were randomized to prasugrel low dose 
(40 mg loading dose, 7.5 mg daily dose), intermediate dose 
(60 mg loading dose, 10 mg daily dose), or high dose (60 mg 
loading dose, 15 mg daily) or standard clopidogrel (300 mg 
loading dose, 75 mg daily dose) for approximately 30 days. 
All patients received aspirin 325 mg daily. The   primary 
endpoint of the study was non-CABG related significant 
hemorrhage, which was defined by the composite of TIMI 
major and minor bleeding criteria. Efficacy was measured 
by the incidence of major adverse coronary events.   Variation 
was not significant in the primary endpoint between the 
combined prasugrel groups and clopidogrel, 1.7% and 1.2%, 
respectively (Hazard Ratio (HR) = 1.42 (95% confidence 
interval (CI) 0.40–5.08), P = 0.59). Major adverse coronary 
events occurred at a similar rate in the combined prasugrel 
arm (7.2%) and clopidogrel arm (9.4%) (HR = 0.76 (95% 
CI 0.46–1.24), P = 0.26). The authors concluded that the use 
of prasugrel resulted in similar bleeding and clinical events 
compared to clopidogrel.
The Prasugrel in Comparison to Clopidogrel for 
  Inhibition of Platelet Activation and Aggregation (PRIN-
CIPLE) Thrombolysis in Myocardial Infarction (TIMI) 
44 Trial was a randomized, double-blind, double-dummy, 
Phase II crossover trial enrolling 201 subjects.24 Patients 
undergoing planned PCI were randomized to treatment 
with prasugrel or clopidogrel with administration of a load-
ing dose within one hour of PCI. The treatment regimens 
were prasugrel 60 mg loading dose and 10 mg daily dose or 
clopidogrel 600 mg loading dose and 150 mg daily dose for 
14 days. After completion of this phase of the study, patients 
were switched to the alternative medication for an additional 
14 days. The primary end point of the loading dose phase 
was the degree of inhibition of platelet aggregation (IPA) 
at 6 hours. Prasugrel had a significantly higher degree of 
IPA (74.8 ± 13%) compared to clopidogrel (31.8 ± 21.1%) 
(P , 0.0001). For the maintenance phase of the study, the 
primary endpoint was degree of IPA at day 14. Results for 
this phase also demonstrated superiority of prasugrel versus 
clopidogrel, 61.3 ± 17.8% and 46.1 ± 21.3%, respectively 
(P , 0.0001). No TIMI major bleeding events were observed 
in either treatment arm during the study period. Thus, both 
Table 2 P2Y12 antagonists
Agent Morphology Mode of 
P2Y12 
inhibition
Reversibility 
of P2Y12 
blockade
Mode of 
administration
Dosing 
frequency
Approval 
status
Ticlopidine Thienopyridine indirect irreversible Oral Twice daily Approved
Clopidogrel Thienopyridine indirect irreversible Oral Once daily Approved
Prasugrel Thienopyridine indirect irreversible Oral Once daily Approved
Ticagrelor Cyclo-pentyl- 
triazolo-pyrimidine
Direct Reversible Oral Twice daily Under review
Cangrelor ATP analog Direct Reversible intravenous During  
procedure
Phase iii 
clinical trials
elinogrel – Direct Reversible Oral and 
intravenous
Once daily Phase ii 
clinical trials
Abbreviations: ATP, adenosine triphosphate; P2Y12,  purinergic.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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the loading and maintenance doses of prasugrel had a greater 
degree of platelet inhibition than high dose clopidogrel.
The positive results of the PRINCIPLE-TIMI 44 trial 
led to a Phase III clinical trial, Trial to Asses Improvement 
in Therapeutic Outcomes by Optimizing Platelet Inhibition 
with Prasugrel (TRITON-TIMI 38).25 TRITON-TIMI 38 
was a 13,608 patient, randomized, double-blinded, multina-
tional Phase III clinical trial designed to assess the efficacy 
and safety of prasugrel versus clopidogrel. Patients with 
moderate to high risk ACS, including NSTEMI and STEMI, 
with scheduled PCI, were randomized to receive either 
prasugrel 60 mg loading dose followed by 10 mg daily or 
clopidogrel 300 mg loading dose followed by 75 mg daily 
for 6 to 15 months. The primary end point was the combined 
occurrence rate of cardiovascular death, nonfatal myocar-
dial infarction, or nonfatal stroke. Non-CABG TIMI major 
bleeding, non-CABG TIMI life-threatening bleeding and 
TIMI major and minor bleeding were the main safety end-
points evaluated. The primary endpoint occurred in 9.9% of 
patients receiving prasugrel and 12.1% of patients receiving 
clopidogrel (HR = 0.81 (95% CI 0.73–0.90), P , 0.001). 
This benefit of prasugrel over clopidogrel was seen as early 
as day 3, which is likely attributed to the rapid onset of 
action of prasugrel. This reduction in the primary endpoint 
was principally driven by a significant reduction in the 
rate of nonfatal myocardial infarction in the prasugrel arm 
(7.3% vs 9.5%; HR = 0.76 (95% CI 0.67–0.85), P , 0.001). 
Other statistically significant endpoints favoring prasugrel 
included urgent target-vessel revascularization (2.5% vs 
3.7%) and stent thrombosis (1.1% vs 2.4%). The overall 
reduction in stent thrombosis was remarkable regardless 
of the type of stent used. There were a significantly greater 
number of non-CABG TIMI major bleeding events with pra-
sugrel than with clopidogrel, 2.4% and 1.8%, respectively 
(HR = 1.32 (95% CI 1.03–1.68), P = 0.03). Additionally, 
there was a greater rate of non-CABG TIMI life-threatening 
bleeding in the prasugrel group (1.4% vs 0.9%; HR = 1.52 
(95% CI 1.08–2.13), P = 0.01), which included fatal (0.4% 
vs 0.1%, HR = 4.19 (95% CI 1.58–11.11), P = 0.002) and 
nonfatal bleeding (1.1% vs 0.9%, HR = 1.25 (95% CI 
0.87–1.81), P = 0.23). CABG-related TIMI major bleeding 
was also higher in the prasugrel treated patients (13.4% 
vs 3.2%, HR = 4.73 (95% CI 1.90–11.82), P , 0.001). 
Three   subgroups, namely   individuals with a history of 
previous stroke or transient ischemic attack (TIA), patients 
75 years or older, and patients weighing 60 kg or less did 
not show favorable clinical benefits from prasugrel due to 
the increased risk of bleeding. In patients with a history 
of cerebrovascular disease, prasugrel was associated with 
an increase in intracranial hemorrhage. Use of prasugrel 
in patients with ACS thus results in a decreased rate of 
clinical events with an increase in bleeding events. In the 
STEMI subgroup study from TRITON TIMI 38, patients 
with STEMI undergoing PCI, prasugrel was found to be 
more effective than clopidogrel for prevention of ischemic 
events, without an apparent excess in bleeding.26
Prasugrel is now indicated to reduce the rate of thrombotic 
cardiovascular events (including stent thrombosis) in patients 
with ACS with planned PCI. The US package insert contains 
a black box warning related to the increased risk of bleeding 
in special populations. The warning recommends against the 
use of prasugrel in patients with active bleeding, prior TIA 
or stroke and the need for CABG surgery. Patients 75 years 
or greater should not receive prasugrel unless the benefit 
outweighs the risk. For patients weighing 60 kg or less, the 
package labeling suggests considering prasugrel 5 mg daily 
even though this dosage was not studied in the TRITON-TIMI 
38 trial. The American Heart Association and the American 
College of Cardiology have issued updates to the guidelines 
for the treatment of STEMI and PCI, which incorporated the 
latest clinical trial results for prasugrel.27 A loading dose of 
prasugrel 60 mg is now recommended for primary PCI in 
STEMI patients as an alternative to clopidogrel. For STEMI 
patients undergoing nonprimary PCI, prasugrel 60 mg may 
be given within one hour after PCI in patients who did not 
receive fibrinolytic therapy and once the coronary anatomy 
is known to avoid using in patients who require CABG. 
After stenting, prasugrel 10 mg daily may be given as an 
alternative to clopidogrel 75 mg daily for at least 12 months 
regardless of stent type and can continue beyond 15 months 
after DES placement. In reference to patients undergoing a 
planned CABG, prasugrel should be held for at least 7 days 
prior to the procedure.
Ticagrelor
Ticagrelor is a reversible oral P2Y12 receptor antagonist, the 
first in a new class known as the cyclopentyltriazolopyrimi-
dines. Since ticagrelor does not require metabolic conversion 
for activity, it has a rapid onset of action within 2–4 hours of 
administration. An active metabolite has been identified for 
ticagrelor, which is believed to contribute to the antiplatelet 
activity of the parent compound. Peak plasma concentrations 
are achieved in 1.5 to 3 hours with steady state being reached 
after 2 to 3 days. As a result of its reversible inhibition at the 
P2Y12 receptor, the mean elimination half-life is 6 to 12 hours 
regardless of dose.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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The pharmacodynamics, pharmacokinetics and safety 
profile of ticagrelor has been studied against clopidogrel 
in the Pharmacodynamics, pharmacokinetics and safety of 
the oral reversible P2Y12 receptor antagonist AZD6140 with 
aspirin in patients with atherosclerosis trial (DISPERSE and 
DISPERSE-2 Phase II trials).28,29 The DISPERSE trial was 
a dose ranging study comparing ticagrelor to clopidogrel in 
patients with stable atherosclerotic disease.28 A total of 200 
patients were randomized to receive ticagrelor (50, 100, or 
200 mg twice a day or 400 mg daily) or clopidogrel 75 mg 
daily for a total of 28 days. Aspirin was given to all patients 
at a dose of 75–100 mg daily. The primary pharmacodynamic 
endpoint was the inhibition of ADP-induced platelet aggrega-
tion at various time points. The degree of platelet inhibition 
with the three highest doses of ticagrelor (100 mg and 200 mg 
twice daily and 400 mg daily) was greater (approximately 
90%–95%) and more rapid than the lowest dose of ticagrelor 
and clopidogrel (approximately 60%). The extent of platelet 
inhibition did not differ among the three highest doses of 
ticagrelor. Bleeding was the most common adverse event and 
occurred more frequently with the higher doses of ticagrelor. 
Dyspnea was a unique side effect found in the ticagrelor 
patients, the incidence of which increased with increasing 
doses, and none of these events were considered serious. 
Ticagrelor 100 mg bid and 200 mg bid were well tolerated 
compared to 400 mg daily with a greater degree of platelet 
inhibition than clopidogrel and lower dose ticagrelor. In the 
DISPERSE-2 trial, a total of 990 patients with NSTEMI 
were randomized to receive ticagrelor or clopidogrel for 
up to 3 months.29 The ticagrelor dose was either 90 mg 
or 180 mg twice daily. Patients in the clopidogrel group 
received a loading dose of 300 mg followed by 75 mg daily. 
All patients received aspirin, initially 325 mg followed by 
75–100 mg daily. The primary safety endpoint of major or 
minor bleeding at 4 weeks did not differ among the groups, 
9.8% in the 90 mg group (P = 0.43 vs clopidogrel), 8.0% in 
the 180 mg group (P = 0.96 vs clopidogrel) and 8.1% in the 
clopidogrel arm. The rate of bleeding in patients undergoing 
CABG less than 5 days after drug administration was lower 
in the ticagrelor arms. Numerically, the rate of myocardial 
infarctions was lower in the ticagrelor arms, but the rate of 
cardiovascular death was similar between the groups. This 
study lacked adequate power to assess clinical events. As 
was seen in the first DISPERSE study, the rate of dyspnea 
was higher in the ticagrelor arms, with 48% of the patients 
having persistent symptoms during the study. Ventricular 
pauses lasting greater than 2.5 seconds was also seen more 
frequently in the ticagrelor arms. The number of patients 
with at least one pause and more than three episodes was 
significantly higher in the 180 mg group than clopidogrel. 
The authors concluded that ticagrelor demonstrated similar 
safety and tolerability to clopidogrel.
The Phase II ONSET/OFFSET trial evaluated the 
timing of the antiplatelet effect of ticagrelor versus clopi-
dogrel in patients with stable coronary disease.30 A total of 
123 patients were randomized to receive ticagrelor 180 mg 
loading dose followed by 90 mg twice daily or clopidogrel 
600 mg loading dose followed by 75 mg daily for 6 weeks. 
Aspirin 75–100 mg daily was given to all patients. At all 
time points, 0.5, 1, 2, 4, 8 and 24 hours after loading and at 
6 weeks, ticagrelor had a significantly greater inhibition of 
platelet aggregation (IPA) (P , 0.0001, all comparisons). In 
addition, two hours after the loading dose was administered 
a greater percentage of patients in the ticagrelor arm had 
achieved .50% IPA (98% vs 31%, P , 0.0001) and .70% 
IPA (90% vs 16%, P , 0.0001). The offset of ticagrelor 
was also faster as evidenced by a comparable IPA result for 
ticagrelor at day 3 to that of clopidogrel at day 5. This study 
demonstrates that ticagrelor has faster onset and offset action 
compared to clopidogrel due its reversible nature.
The largest and latest Phase III trial of ticagrelor (platelet 
inhibition and patient outcomes (PLATO)) compared ticagre-
lor and clopidogrel in patients with or without STEMI.31 A 
total of 18,624 patients were randomized to ticagrelor 180 mg 
loading dose followed by 90 mg twice daily or clopidogrel 
300 mg loading dose followed by 75 mg daily. In patients 
who had PCI, an additional dose of assigned study drug 
was given, either ticagrelor 90 mg or clopidogrel 300 mg. 
Aspirin 75–100 mg daily was given to all patients, unless 
post stent, in which case 325 mg daily was permitted for six 
months. The primary efficacy endpoint was a composite of 
death from vascular causes, myocardial infarction or stroke. 
Safety was measured as the first occurrence of a major 
bleeding event using the study specific criteria. The rate of 
vascular events at 12 months occurred at a lower rate in the 
ticagrelor group (9.8%) compared to the clopidogrel group 
(11.7%) (HR = 0.84 (95% CI 0.77–0.92), P , 0.001). This 
endpoint was driven by statistical reductions in the rate of 
MI and vascular death in the ticagrelor arm. Death from any 
cause, predefined as a secondary endpoint, occurred in 4.5% 
of ticagrelor patients versus 5.9% of clopidogrel patients 
(HR = 0.78 (95% CI 0.69–0.89), P , 0.001). The rate of 
stent thrombosis in patients who received a stent during the 
study was lower with ticagrelor (1.3%) over clopidogrel 
(1.9%) (HR = 0.67 (95% CI 0.50–0.91), P = 0.009). The rate 
of major bleeding events as defined by the PLATO investi-Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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gators, did not differ significantly between ticagrelor and 
clopidogrel, 11.6% and 11.2%, respectively (HR = 1.04 (95% 
CI 0.95–1.13), P = 0.43). When the TIMI criteria for major 
bleeding were analyzed, the lack of difference between the 
treatment arms persisted (7.9% vs 7.7%; HR = 1.03 (95% 
CI 0.93–1.15), P = 0.57). The rate of CABG-related bleed-
ing using both the study definition and TIMI criteria was 
similar in both arms (both, P = 0.32). Non-CABG related 
major bleeding was significantly higher with ticagrelor 
using the study criteria (4.5% vs 3.8%, HR = 1.19 (95% CI 
1.02–1.38)) and TIMI criteria (2.8% vs 2.2%, HR = 1.25 
(95% CI 1.03–1.53)) (P = 0.03, both endpoints). Other 
adverse events seen in the PLATO trial were similar to those 
seen in previous studies. Dyspnea was more commonly seen 
with ticagrelor, 13.8% versus 7.8% (P , 0.001), although 
only 0.9% of the ticagrelor patients discontinued therapy as 
a result of this side effect. During the first week of therapy 
there was a significantly higher incidence of ventricular 
pauses greater than or equal to 3 seconds in the ticagrelor 
arm (5.8% vs 3.6%, P = 0.01). In this study, uric acid and 
serum creatinine values were increased in the ticagrelor 
arm for the duration of treatment but similar to clopidogrel 
one month after discontinuing therapy. The authors con-
cluded that ticagrelor significantly reduced the incidence 
of vascular events without a significant increase in the rate 
of major bleeding.
Cangrelor
Cangrelor is also a reversible, nonthienopyridine P2Y12 recep-
tor antagonist. Unlike, the other P2Y12   inhibitors,   cangrelor 
is being developed as an intravenous (IV)   formulation. 
Cangrelor does not require metabolic conversion, which 
results in its ultra-short half-life of approximately 2.6 to 
3.3   minutes. This short half-life allows the effects of can-
grelor to be offset within 20–50 minutes following cessation 
of the   infusion. Given the drug’s unique properties, studies 
have been conducted in the setting of ACS and PCI. Can-
grelor was studied in a Phase II trial compared to placebo in 
patients with unstable angina and non-Q wave MI.32 In this 
study, cangrelor was well tolerated and bleeding rates were 
  similar to placebo. The use of cangrelor in patients undergo-
ing urgent or elective PCI was studied in a 2-part Phase II 
trial enrolling a total of 399 patients.33 Results from the first 
part of the study showed cangrelor to have a similar rate of 
bleeding compared to placebo. The second part of the study 
was a head to head comparison with abciximab. Bleeding 
rates were comparable between cangrelor and abciximab. 
Platelet inhibition with cangrelor was seen within 15   minutes 
of starting the infusion and platelet function returned to 
baseline within 15 minutes of stopping the infusion. Platelet 
inhibition in the abciximab arm was seen 24 hours after the 
infusion was terminated, as expected.
STEP-AMI (Safety, Tolerability and Effect on Patency in 
Acute Myocardial Infarction) examined the use of cangrelor 
alone or in combination with low dose alteplase (tPA) to 
standard dose tPA.34 This study was stopped early due to a 
shift in drug development by the manufacturer. Preliminary 
results indicated improved coronary artery patency in the 
patients who received cangrelor and tPA over cangrelor alone 
but no benefit compared to tPA alone.
Two larger scale, Phase III randomized trials of cangrelor 
versus standard therapy to achieve optimal management of 
platelet inhibition (CHAMPION) were recently published.35,36 
These studies (CHAMPION PLATFORM and   CHAMPION 
PCI) enrolling over 14,000 patients were terminated early by 
the manufacturer when interim efficacy analysis indicated 
no benefit of cangrelor over placebo. The study designs were 
similar with the exception of clopidogrel timing. In CHAM-
PION PCI, clopidogrel was given before PCI, whereas in 
CHAMPION PLATFORM, clopidogrel was given after PCI. 
The primary efficacy endpoint was a composite of death, MI 
or ischemia driven revascularization, which did not differ 
between cangrelor and placebo. An interesting finding was 
the rate of stent thrombosis, which was significantly reduced 
by cangrelor in the CHAMPION PLATFORM study but not 
the CHAMPION PCI study. The manufacturer of cangrelor 
has changed the focus of their research to investigate the role 
of cangrelor as bridge therapy when an antiplatelet therapy is 
needed short term, when oral drugs cannot be used, or when a 
short drug half-life is needed (for example, in bridging patients 
on drugs like clopidogrel who need to undergo surgery). The 
  ongoing maintenance of platelet inhibition with cangrelor 
after   discontinuation of thienopyridines in patients undergo-
ing surgery (BRIDGE) study is investigating this strategy and 
will enroll approximately 200 patients.37
elinogrel (PRT 060128)
PRT 060128 or elinogrel is the only direct acting, reversible 
P2Y12 antagonist with a unique structure that is being studied 
both as an IV and oral form. Thus it has the potential of being 
administered IV in the hospital, and then switched over to the 
oral form for   continuation of therapy. Elinogrel is directly 
active without the need for any transformation. Most of the 
drug is excreted unchanged in the urine and feces. About 
10%–20% of the drug is metabolized by demethylation (PRT 
060301), and is the only prominent circulating metabolite in Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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plasma. In an initial   pharmacokinetic and pharmodynamic 
study, single IV doses of elinogrel between 1 and 40 mg 
were administered over 20 minutes to 5 groups of 8 healthy 
subjects (6 active, 2 placebo) in a randomized,   double-blinded 
fashion.38 Platelet aggregation with 10 µM ADP at 6 minutes 
was measured. All IV doses were well tolerated with no 
serious or clinically significant adverse events. The increase 
in plasma drug concentration of elinogrel is dose related, 
and the degree of platelet inhibition is also proportional to 
plasma drug concentration. The maximum tolerated dose 
using a pre-defined bleeding time criteria was reached with 
the 40 mg dose. Average terminal half-life of the 40 mg dose 
of elinogrel was about 11 hours.
In an animal model (mouse model), the efficacy of PRT 
060128 (PRT 128) and clopidogrel were compared by Andre 
et al.39 Mice were administered PRT 128 (7.5, 20, 60 mg/kg) 
2 hours prior to experiments or clopidogrel 50 mg/kg for 3 days 
with 5–10 animals per group. Bleeding times and thrombosis 
were measured. PRT 128 demonstrated   dose-proportional anti-
thrombotic activity in vivo at plasma concentrations which had 
minimal effect on tail bleeding times. At the highest concentra-
tions of PRT 128, its antithrombotic activity was superior to 
clopidogrel. This finding of superior efficacy of PRT 128 was 
further evaluated in human subjects by Gurbel et al.40 A total 
of 45 subjects with established coronary artery disease with 
previous coronary stent placement on chronic aspirin and 
clopidogrel therapy were screened for high platelet reactivity 
(HPR) defined as .43% platelet aggregation to 5 µM ADP. 
A total of 20 out of these 45 patients had HPR. Following 
administration of single oral dose of 60 mg PRT 128, plate-
let function was assessed at baseline, 4 hours, 6 hours, and 
24 hours post-dosing with several pharmacodynamic assays. 
Platelet reactivity fell within 4 hours of dosing, the earliest time 
point evaluated, and was reversible within 24 hours. Elinogrel 
thus reversibly overcomes high platelet reactivity seen as 
a result of nonresponsiveness to dual antiplatelet therapy 
with clopidogrel and aspirin. A simultaneous assessment of 
CYP2C19*2 showed a more frequent association with HPR 
(77% versus 16%, P = 0.0004).
The safety and feasibility of IV elinogrel before primary 
PCI for STEMI as an adjunctive antiplatelet therapy was 
studied in a Phase II trial (the Early Rapid Reversal of Platelet 
thrombosis with IV elinogrel before PCI to optimize reper-
fusion in acute myocardial infarction (ERASE MI).41 This 
was a pilot, randomized, placebo-controlled, dose-escalation 
study designed to study tolerability of single, IV elinogrel 
in escalating doses (10 mg, 20 mg, 40 mg, and 60 mg). All 
patients received aspirin,   unfractionated heparin, and 600 mg 
clopidogrel given after diagnostic angiogram but before PCI, 
and another 300 mg 4 hours after PCI. Other antithrombotic 
agents were not allowed while the use of glycoprotein IIb/IIIa 
inhibitors was strongly recommended. A total of 70 patients 
in four cohorts were enrolled. The primary outcome was in-
hospital   bleeding per the TIMI and GUSTO bleeding scales. 
The incidence of bleeding events was low, and similar with 
all doses of elinogrel versus placebo. There were no differ-
ences in serious adverse events with elinogrel compared to 
placebo.
A Phase II safety and efficacy study of elinogrel is 
  currently ongoing (INNOVATE-PCI).42 This is a multicenter, 
  randomized, double-blind, triple-dummy, clopidogrel-
  controlled study of IV and oral PRT 060128 compared to 
clopidogrel in patients undergoing nonurgent (including elec-
tive) PCI. After diagnostic angiography, patients scheduled 
for nonurgent PCI will be randomized to clopidogrel or to 
one of three dose levels of elinogrel.
Thrombin receptor antagonists
Thrombin is the main mediator of blood coagulation, first 
in the initial platelet activation, and then in the amplifica-
tion and cleavage of fibrinogen to fibrin. Thrombin is also 
the most potent platelet activator, activating platelets at 
an extremely low concentration (lower that those required 
for activation of the coagulation cascade). Thrombin is 
not influenced by P2Y12 receptor antagonists or aspirin. 
Selective blocking of the thrombin receptor effectively 
inhibits thrombin dependent platelet activation (the path-
way involved in thrombosis). However, selective thrombin 
receptor blockade spares the collagen dependent activation 
of the pathway involved in hemostasis. This blockade does 
not affect the generation of fibrin by thrombin and throm-
bin’s effects on coagulation factors are spared. Proteinase 
activated receptor-1 (PAR-1) is a   high-affinity receptor for 
thrombin, and the key platelet thrombin receptor. Throm-
bin acts on PAR-1 by cleaving the N-terminal domain, and 
then exposing a tethered ligand that binds and activates the 
receptor. Thus, thrombin   receptor antagonists by selectively 
inhibiting PAR-1 portend to cause a favorable balance of 
antithrombotic efficacy with less risk of bleeding. Inhibition 
of thrombin-mediated PAR-1   activation could add a new 
dimension in the domain of antiplatelet therapy. In addition, 
PAR-1 is also expressed in endothelial cells, cardiomyocytes, 
and smooth muscle cells. It acts as a modulator in acute 
inflammation and vascular repair. Thus, PAR-1 blockade 
may also be of interest in healing following PCI to reduce 
in-stent re-stenosis.43Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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SCH 530348 (also known as vorapaxar), an orally active, 
low-molecular weight, nonpeptide, competitive PAR-1 
antagonist (tricyclic 3-phenylpyridine antagonist) potently 
inhibits thrombin-induced platelet aggregation without 
affecting measures of coagulation or increasing bleeding 
time. Both the association and dissociation rates of SCH 
530348 with PAR-1 are slow, yet the inhibition is reversible 
and dose-dependent. A SCH 530348 loading dose of 20 mg 
achieves .80% inhibition of thrombin receptor activating 
peptide (TRAP)-induced platelet aggregation at 2 hours in 
approximately 50% of patients. With a 40 mg loading dose, 
nearly 70% patients had .80% inhibition after 1 hour and 
96% by 2 hours. Both the 1 and 2.5 mg maintenance doses 
sustained .80% inhibition at 30 and 60 days in all patients 
tested. Recovery of platelet function to 50% of baseline 
after a single dose occurs slowly in a dose dependent 
manner (1, 2, and 3 weeks after 10, 20, and 40 mg doses 
respectively). In patients receiving a maintenance dose of 
2.5 mg daily for 28 days, recovery of platelet function was 
observed 2 to 3 weeks after the last dose. SCH 530348 is 
rapidly absorbed, and has excellent bioavailability upon oral 
administration with a pharmacodynamic half life of greater 
than 7 days. It is metabolized and eliminated primarily by 
biliary and gastrointestinal routes. Renal clearance is less 
than 5%, thus clearance is no different among healthy and 
renally impaired patients. Exposure to SCH 530348 is dose 
dependent with an inter-individual variability of 20%–40% 
that does not depend on sex, ethnicity or fasting state. It is 
slowly, but extensively metabolized mostly via oxidation 
by the CYP3A4 system. Co-administration with ketocon-
azole and rifampin increases and decreases its exposure 
respectively.44,45
In the Phase II thrombin receptor antagonist –   percutaneous 
coronary intervention (TRA-PCI) trial, the safety and efficacy 
of SCH 530348 among 1,031 patients undergoing nonurgent 
PCI or coronary angiography with intention to perform PCI 
were evaluated during a 60-day period.46 In addition to aspirin 
and clopidogrel, and heparin or bivalirudin, patients were 
randomized to receive one of the three loading doses of SCH 
530348 (10 mg, 20 mg, or 40 mg) or placebo at least 1 hour 
before PCI. Patients that underwent PCI (n = 573) were ran-
domized to receive one of the three oral daily   maintenance 
doses of SCH 530348 (0.5 mg, 1 mg, or 2.5 mg) or placebo 
for 60 days. The primary end point was the composite of 
TIMI major or minor bleeding in the PCI cohort. Overall, 
SCH 530348 did not cause an increase in the occurrence 
of the primary safety end point compared to placebo (3.3% 
with placebo versus 2.8% combined SCH 530348 groups). 
The rates of bleeding by maintenance dose were also similar. 
Among patients undergoing CABG, CABG-related bleeding 
was similar between SCH 530348 and placebo. The secondary 
end point of death, major cardiovascular events or stroke was 
also similar between SCH 530348 and placebo.
Another Phase II clinical trial of 117 Japanese NSTEMI 
patients receiving aspirin, ticlopidine and heparin, found 
that the addition of SCH 530348 (20 mg or 40 mg loading 
followed by 1 mg or 2.5 mg maintenance dose) for 60 days 
did not cause an increase in the primary end point of TIMI 
major and minor bleeding compared to placebo.47 Evidence 
from these two trials show that SCH 530348 when added to 
current standard of care therapy, does not cause increased 
bleeding, and may even offer a potential benefit of lowering 
thrombotic events.
Two Phase III trails are currently ongoing with 
SCH 530348. The Thrombin Receptor Antagonist for 
  Secondary Prevention (TRA-2 degrees P-TIMI 50) trial is 
a   double-blind, randomized, placebo controlled trial that 
will evaluate the efficacy of SCH 530348 plus standard-
of-care therapies in secondary prevention with prior MI, 
stroke or   peripheral vascular disease.45 Planned enroll-
ment will be 20,000 patients, randomized to receive SCH 
530348 2.5 mg or placebo for a minimum of 1 year. The 
primary end point is the composite of cardiovascular 
death, MI, urgent coronary revascularization or stroke. The 
Thrombin Receptor Antagonist Clinical Event reduction in 
acute   coronary syndrome (TRACER) is a double-blinded, 
placebo-controlled trial of .10,000 patients with NSTEMI 
that will compare 40 mg loading dose of SCH 530348 
and 2.5 mg   maintenance dose versus matching placebo in 
addition to aspirin and clopidogrel for at least 1 year.48 The 
primary end point is the composite of cardiovascular death, 
MI, stroke, re-hospitalization for ACS, and urgent target 
revascularization during a minimum 1-year follow up. The 
estimated completion date is July 2011.
Another PAR-1 receptor inhibitor E5555 is currently 
being tested in Phase II safety studies. E5555 is a potent 
PAR-1 antagonist that targets the G-coupled receptor modu-
lating thrombin-platelet-endothelial interactions. This drug 
was studied in a Phase II trial among healthy volunteers 
and patients with CAD treated with aspirin with or without 
  clopidogrel.49 Platelet activity was assessed after pre-incuba-
tion with escalating concentrations of E5555 (20 ng/ml, 50 
ng/ml, and 100 ng/ml) in healthy volunteers, CAD patients 
treated with aspirin, and CAD patients treated with aspirin 
and clopidogrel combination (n = 10, for each group). 
E5555 inhibited a number of platelet biomarkers. Platelet Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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inhibition was usually moderate, and was not seemingly 
dose-dependent without TRAP stimulation. E5555 caused 
10%–15% inhibition of ADP- and collagen-induced platelet 
aggregation in plasma, but not in whole blood. TRAP-induced 
aggregation was inhibited almost completely. E5555 poten-
tiates the antiplatelet effects of aspirin alone, and also the 
combination of aspirin and clopidogrel. E5555 thus promises 
to be a potential addition to current antiplatelet therapy.
Phosphodiesterase inhibitors
Cilostazol is a phosphodiesterase (PDE) III inhibitor that 
is   currently indicated as a first line agent among patients 
with intermittent claudication due to its beneficial effect on 
  increasing claudication distance.50 In addition to its antiplate-
let effects, it also possesses antiproliferative properties by 
  reducing smooth muscle proliferation and intimal hyperpla-
sia following endothelial injury. Recent studies have shown 
benefits of cilostazol as triple therapy in addition to aspirin 
and clopidogrel in reducing major cardiac adverse events 
in patients with acute coronary syndrome and following 
PCI.51,52
NT-702 (parogrelil hydrochloride), a selective phos-
phodiesterase (PDE)-3 inhibitor has vasodilatory as 
well as anti-inflammatory properties. In in-vitro studies, 
NT-702 potently and concentration-dependently inhibited 
human platelet aggregation induced by ADP, collagen, 
and thrombin. It is being studied for the treatment of 
claudication.53
Thromboxane-prostaglandin  
receptor (TP) antagonist
TP receptor antagonists block the effects of   thromboxane 
on platelets, monocytes, and vascular endothelium while 
  allowing endothelial prostacyclin production via the COX-1 
pathway. In addition, they also inhibit other thromboxane 
receptor ligands such as endoperoxidase, prostanoids, and 
isoprostanes. These agents thus cause vasodilation, and 
inhibit platelet aggregation.
Terutroban (formerly S18886) is an oral, reversible TP 
receptor antagonist with antithrombotic, antivasoconstrictive, 
and antiatherosclerotic properties.54 Terutroban provides fast 
and potent antithrombotic effects comparable to that provided 
by aspirin–clopidogrel   combination with a more favorable 
bleeding risk profile. In a pharmacokinetic–pharmodynamic 
study, the maximal inhibitory effect was achieved in 1 hour 
after dosing in patients with peripheral arterial disease.55 
A large, Phase III trial (PERFORM) is currently comparing 
the efficacy and safety of terutroban versus aspirin in second-
ary prevention of cardiovascular and cerebrovascular events 
in patients with recent history of stroke or TIA.56,57
Serotonin receptor blocker
Serotonin causes platelet aggregation and vasoconstriction. 
Sarpogrelate, a selective 5-hydroxytryptamine 2A (5-HT2A) 
receptor antagonist has been developed as an antiplatelet agent 
and has been used in Japan, China and Korea for many years 
in patients with peripheral vascular disease (PVD). In a Phase 
II study with this drug in Europe for intermittent claudication, 
this drug was well tolerated, and had shown a trend towards 
improving claudication distance.58 This drug is shown to be 
noninferior and safer than aspirin in stroke patients.59
Platelet adhesion antagonist
von Willebrand factor (vWF) is vital to platelet adhesion and 
aggregation. ARC-1779 is an optimized, second-generation, 
PEGylated aptamer that exerts a novel antithrombotic action 
through targeting the A1 domain of activated vWF and 
inhibiting the binding of platelet receptor glycoprotein Ib. It 
thus reduces platelet adhesion, and aggregation and thereby 
thrombus formation in arterial beds. ARC-1779 has potential 
therapeutic benefit in acute coronary syndromes and von 
Willebrand’s disease, as well as in vWF-related platelet dis-
orders such as thrombotic thrombocytopenic purpura (TTP) 
and other thrombotic microangiopathies. As an aptamer, the 
actions of ARC-1779, unlike other antiplatelet agents, can 
be readily reversed by binding to a complementary sequence 
of oligonucleotides; this ability offers potential therapeutic 
benefit in surgery.
In Phase I and II clinical trials, ARC-1779 has exhibited 
favorable pharmacokinetic, pharmacodynamic and safety 
properties in healthy individuals and patients with TTP. The 
first-in-human evaluation of ARC1779 has shown a dose- 
and concentration-dependent inhibition of vWF activity and 
platelet function with a duration of effect suitable for the 
intended clinical use in acute coronary syndromes.60 Even in 
the setting of acute myocardial infarction, where vWF is 
increased, ARC1779 potently and specifically inhibits vWF 
activity and vWF dependent platelet function.61 The study 
entitled, ARC1779 in Patients with acute myocardial infarc-
tion undergoing PCI (vITAL-1), has been terminated.62
Nitric oxide-releasing aspirin
The addition of a nitric oxide-releasing moiety to aspirin 
would offer added benefit beyond the antiplatelet effects of 
aspirin since nitric oxide has a combination of antithrombotic, 
antiatherogenic and vasodilatory effects. NCX-4016 is a Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
88
Das et al
prototype of this family of molecules. NCX-4016 undergoes 
first pass metabolism in the liver, and is metabolized to sali-
cylic acid and NCX-4015. NCX 4016 has been effective in 
the inhibition of COX activity and also   monocyte activation 
with tissue factor expression. In a rat model of carotid balloon 
injury treatment, NCX-4016 resulted in increased availability 
of nitric oxide and a lower rate of restenosis, when compared 
with that of aspirin. This effect was associated with diminished 
vascular smooth muscle cell proliferation. This agent also has a 
better gastroenteric safety profile as compared to aspirin alone. 
In a prospective, randomized, single-blind, parallel-group trial 
among 44 patients with intermittent claudication comparing 
4 weeks of therapy with NCX 4016 (800 mg BID) versus 
aspirin 100 mg daily, exercise induced endothelial dysfunction 
was prevented by NCX 4016, but not by aspirin.63
Glycoprotein vi antagonist
After vessel wall disruption, platelets are adhered to 
  subendothelial collagen through the glycoprotein VI (GPVI) 
receptors, and subsequently are activated. PR-15 is a soluble 
variant of GPVI receptor. It is a monoclonal antibody to GPVI 
receptor. It binds to exposed collagen and prevents GPVI 
mediated firm platelet adhesion and activation. Unlike other 
antiplatelet drugs, PR-15 targets receptors that are found on 
the activated platelets, which may potentially reduce the risk 
of bleeding associated with antiplatelet agents. In vitro studies 
have evaluated the ability of PR-15 to inhibit human platelet 
aggregation. The degree of reduction of   aggregation produced 
was similar to the highest concentration regardless of col-
lagen addition. PR-15 did not increase bleeding time in vitro. 
It has shown to be safe in   animal models. A Phase I study of 
30 healthy volunteers has been completed and the pharma-
cokinetics and pharmacodynamics (platelet aggregation) of 
six ascending single IV doses of PR-15 have been assessed.64 
This study has been terminated by the company and no further 
details are available.
Cyclooxygenase inhibitors
Indobufen, a potent but reversible platelet COX-1 inhibitor 
has been shown to be effective as an   antithrombotic agent. 
It was shown to be effective in   prevention of graft occlu-
sion after CABG and for the prevention of thromboembolic 
events in coronary artery   disease.65 Studies comparing 
indobufen to warfarin for prevention of stroke have not 
been very compelling for indobufen as it caused slightly 
higher stroke events.66
Table 3 details the nonpurine antagonists as they are 
being developed for clinical use. Table 4 enlists the phar-
macological properties of promising antiplaletet agents.
Discussion
Among the newer antiplatelet agents discussed in this 
review, prasugrel has already been approved for clinical 
use, while ticagrelor is expected to be available in the near 
future. Since prasugrel produces a more thorough inhibi-
tion of platelet aggregation with a faster onset of action 
without much variability in response, it should be the drug 
of choice in an ideal patient following percutaneous coro-
nary intervention. However, prasugrel’s use is somewhat 
limited by the fact that it causes more bleeding particu-
larly among patients over 75 years of age, and patients 
weighing less than 60 kg. Prasugrel is contraindicated in 
patients with a prior history of stroke or TIA. Ticagrelor 
offers a distinct advantage over currently available P2Y12 
receptor antagonists, in that it is a reversible agent with a 
fast onset of action while not causing an increased risk of 
bleeding. The unique side effects of dyspnea, ventricular 
pauses and laboratory changes do not appear to be clinically 
significant, but warrant closer and long-term monitoring. 
While   cangrelor is unique due to its IV formulation and 
short   half-life, making it attractive for use during PCI, 
two Phase III trials showed no significant advantage of 
this drug over conventional therapy. Its role as a bridging 
Table 3 Newer antiplatelet compounds in clinical trials
Agent Target Phase of development Indications
SCH530348 Thrombin receptor PAR-1 Phase iii Acute coronary syndrome 
Cardiovascular disease
e5555 Thrombin receptor, PAR-1 Phase ii Acute coronary syndrome
Terutroban (S18886) Thromboxane receptor Phase iii Stroke: secondary prevention
Cilostazol Phosphodiesterase iii Phase iv Approved for PvD 
Trials for PCi, stroke, DM
Sarpogrelate 5-HT2A serotonin inhibitor Phase iv Approved for PvD in Japan 
Trials for PCi, stroke
Abbreviations: DM, diabetes mellitus; PAR-1, protease-activated recepter-1; PCi, percutaneous coronary intervention; PvD, peripheral vascular disease; 5-HT2A, 
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therapy prior to surgery is being defined. Elinogrel on the 
other hand will be available in both an oral and IV form. If 
  supported by the ongoing Phase II and III trials, elinogrel 
holds a great promise in interventional cardiology as this 
can be used as an IV form during PCI, transitioning to an 
oral form for maintenance therapy. The most ideal, and 
probably the most promising of all the emerging antiplatelet 
agents are the thrombin receptor antagonists. As these new 
agents have an excellent safety profile with less bleeding, a 
positive efficacy outcome from the ongoing trials will herald 
a new era in the field of antiplatelet therapy. The other agents 
discussed in this review await further clinical data to define 
their role in present atherosclerotic disease management.
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